$EGRX on Be prepared for possible Growth
As Eagle Pharma Win Patent Decision for Bendeka, Court issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl , a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride. So with that 
EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy and safety of the medicament, EGRX is showing a good and healthy growth at stock market.
EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy and safety of the medicament, EGRX is showing a good and healthy growth at stock market. 
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.